Ipatasterib in the treatment of mCRPC: now in Phase III trial

Ipatasterib is a new type of drug that can be used to block the so-called PI3K/Akt signaling pathway, which is often highly activated in men with metastatic, castration-resistant prostate cancer (mCRPC). … REAF MORE…